Good day and welcome to the fourth quarter and FY 2024 Cardinal Health Incorporated earnings conference call. My name is George and I’ll be your coordinator for today’s event. Please note that this conference is being recorded and for the duration of the call, your lines will be in listen-only mode; however, you will have the opportunity to ask questions at the end of the presentation. This could be done by pressing star, one on your telephone keypad to ask your question. In order to allow as many people as possible to ask a question, we ask that you please limit yourselves to one question each. If you require assistance at any point, please press star, zero and you will be connected to an Operator. I’d now like to hand the call over to your host today, Mr. Matt Sims, Vice President of Investor Relations. Please go ahead, sir.

Welcome to this morning’s Cardinal Health fourth quarter and fiscal ’24 earnings conference call, and thank you for joining us. With me today are Cardinal Health’s CEO, Jason Hollar, and our CFO Aaron Alt. You can find this morning’s earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in the statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statements slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis unless specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedule attached to our press release. For the Q&A portion of today’s call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason.

Thanks Matt and good morning everyone. Fiscal year ’24 marked a year of strong operational execution and record financial results for Cardinal Health, delivered in tandem with significant strategic progress across the portfolio. On that note, we have three key headlines today. First, we finished the year with momentum, growing EPS 29% in both Q4 and fiscal year ’24. Our results exceeded guidance and full-year EPS of $7.53 was $0.96 above the midpoint of our original outlook from investor day. We also delivered nearly $4 billion of adjusted free cash flow for the year, positioning us with approximately $5 billion of cash at year end, even after $1.25 billion of capital returned to shareholders this year and funding our growth investments. Second, we have managed through the transition of a significant customer and are raising our guidance for fiscal year ’25, while also reconfirming our long term financial targets. Finally, we continue to advance our strategy to build upon the growth and resiliency of pharma and specialty, execute our GMPD improvement plan, and accelerate our growth in key areas while optimizing our portfolio to maximize shareholder value creation. More on that momentarily, but first some brief reflections. This year, we continue to take decisive actions to simplify our business and drive performance, highlighted by the reorganization of our operating and segment reporting structure to enhance management focus while enabling efficiencies, accountability and transparency. We grew our largest and most significant business, pharmaceutical and specialty solutions, above our targeted long term growth rate. We saw ongoing stability in pharmaceutical demand, strong performance from our generics program, and our specialty business grew revenue 14% for the year. As of fiscal year ’24, our specialty business is now over $36 billion and we anticipate continued growth next year despite a large contract expiration.…

Thank you Jason, and good morning. Before discussing our Q4 success and our raised guidance, I want to highlight that today, we are providing revised prior period financials for fiscal year ’22 through Q3 fiscal year ’24, reflecting slight net increases to non-GAAP EPS. During the preparation of our annual financial statements, management identified a longstanding accounting error in part of our at-home solutions business related to revenue recognition from third party payors. As a result, we have corrected this item in prior periods and also updated the timing of other previously recognized immaterial out-of-period items across the full enterprise. The net impact of these changes increases non-GAAP EPS by $0.07 in fiscal year ’24, $0.06 in fiscal year ’23, and $0.01 in fiscal year ’22. To be helpful, we’ve included supplemental schedules in our press release along with further detail in our fiscal year ’24 10-K. Moving to our results, I am pleased to reinforce that Q4 produced a strong finish to a year in which the Cardinal team made tremendous progress against our financial and strategic priorities. For both Q4 and the year, our EPS results reached historical high points with operating profit growth across pharma, GMPD and other, also supported by improvements below the line in the form of lower interest costs, better tax rates, and lower share count. We delivered strong gross margin growth and matched it with well controlled SG&A, even in an inflationary environment. In Q4, revenue increased 12% to $59.9 billion, reflecting revenue growth in the pharmaceutical and specialty solutions segment, the GMPD segment, and in all of the businesses making up other. Gross margin grew 5% to $1.9 billion, outpacing consolidated SG&A which increased only 2% to $1.3 billion in the quarter, reflecting our disciplined cost management. This translated to total company…

Thanks Aaron. Now I’ll go deeper into our strategic priorities, beginning with pharma and specialty solutions, where we remain focused on building upon our strong core foundation and expanding in specialty. Everything we do starts with the customer. Recently we hosted our 32nd annual retail business conference, the largest in the industry, bringing together 5,000 attendees from across the country. As the trusted partner to retail pharmacy, we understand the critical role retail independent pharmacies play in caring for their communities as they continue to expand their services as community healthcare destinations and demonstrate their remarkable value and resiliency. We continue to invest in our full suite of clinical, business and reimbursement solutions to support our customers and provide industry advocacy to empower retail pharmacy, now and into the future. Our consumer health logistics center slated to open in 2025 will offer a comprehensive selection of over-the-counter medications, treatments and diagnostic solutions. Additionally, our new vaccine alliance program offers cost savings and other benefits from participating manufacturers to help pharmacies engage more patients and expand their immunization programs. We are constantly evaluating ways to bring innovative solutions to our pharmacy and manufacturer partners through the breadth of our offerings and capabilities. As part of that commitment and in collaboration with CVS Health, we have formed Averon, a joint venture to source biosimilars. Averon builds upon our company’s successful partnerships like Red Oak Sourcing with similar overall objectives for biosimilars. Simply put, we are increasing access to additional therapy options that will provide more choice for patients at a lower cost. Averon began by contracting a couple of products, including Humira biosimilars, and we see opportunities for the program to expand over time. Continuing in specialty, we’re pleased with how quickly specialty networks has integrated with our business, and we continue…

Thank you very much, Mr. Hollar. [Operator instructions] Today’s first question is coming from Lisa Gill, calling from JP Morgan. Please go ahead.

Thanks very much, and good morning. Thanks for all the details, Jason. I just want to better understand two things. One, nice driver of the margin going into next year, you had originally said roughly 1%, now you’re talking 1% to 3%. I think you called out a couple of things - the specialty network, new customer, cost mitigation, but I’m just curious, especially in the new customer, is there anything unique about that contract or anything else that you would call out as we think about the margin improvement throughout ’25?

Lisa, good morning, thanks for the question. Happy to talk about it. We are really pleased to raise our guide for the pharma business for fiscal ’25 - it really reflects our continued confidence in the team and continued confidence in the resiliency of that business, notwithstanding some of the puts and takes that we’ve been talking about over the last couple of quarters. I’ll touch on the profile in a second, but I do want to emphasize on the revenue side of the house from a guidance perspective that we guided down 4% to 6% all-in, reflecting the $40 million headwind on the low margin contract non-renewal, but it’s really up 15% to 18% on an adjusted basis if you take out the impact of that customer loss. Within that 15% to 18% is $10 billion of new revenue, new customers and expansions of service with existing customers - that’s on top of a 10% underlying growth with the existing business, and so from that you can tell that we are growing the portfolio and doing what we said we were going to do with our existing customers and adding on both new customers and expansions with existing customers to get to that revenue base. That supports the increase in guide, the 1% to 3% on the profitability side of the house. The thing we called out during the earnings call is the consistent market dynamics, it’s the generic volume growing, the low single-digit growth in core and the high single-digit growth in specialty, the strong overall Rx demand. There’s a lot of things going on, but we are confident in our plans as we carry forward. Now, we don’t comment on the margin profile of any particular customer, particularly in the context of a new customer, and we were delighted to announce formally the Publix win today in our earnings release. I’m not going to comment on their profitability, but I will observe that we have publicly commented on the low margin nature of the business that we’ve lost, and that certainly doesn’t hurt us as we carry forward. Jason, anything you would add to that?

No, nothing to add.

Thank you. Our next question will be coming from Eric Percher calling from Nephron Research. Please go ahead.

Thank you. I think it’s fair to say there was some concern coming into the quarter on the increase in macro freight trends and other input costs, and I know you mentioned you’re able to offset that. Can you give us a sense of how this looked to you in terms of the size of that increase versus what we’ve seen in the past, was it material, and how it looked under the current or new contracts versus legacy contracts, and the ability to pass that along to your customers?

Sure, thanks for the question, Eric. I think it’s important to just go back in time a little bit, this last 12 months. A year ago when we were sitting here, certainly the freight costs had gone all the way back down to historic levels, so we were enjoying--really, the run-up had come all the way back down, and it was the beginning of the calendar year, so in our third quarter when the Red Sea issues first began, and that’s when we saw the first spike, and the reason I remind you of that is that first spike was known come springtime, when we gave our initial guidance for GMPD, and so we knew about that first step-up already, and that’s been factored into the guidance from day one. Yes, there have been further increases since then, but when you look at the combined two increases, the two different steps, first in January, then in the spring, they still are woefully short of where we were a couple of years ago when the whole supply chain was under pressure, where even when we were spending two, three times the current level, we were having difficulty in actually getting reasonable service. So yes, the costs are higher, but not nearly as high as they used to be, and most importantly is the supply chain is functioning a lot more efficiently than it was before. Long way of saying, Eric, that yes, there is a little bit of an increase here, it’s something we monitor and manage very, very tightly, but it’s not the point where it requires widespread price adjustments accordingly, at least not yet. In addition to that, it’s important that we look at the overall inflationary environment, and we talked about this a couple of years ago. At the peak, we had a lot of oil and petroleum-based products, including fuel and other type of freight, that was also a big issue. Those are actually a little bit softer in terms of the cost, so overall net-net, we’re managing through it better than we have before, and overall we have some puts and takes that are all very manageable. We’ll continue to evaluate the pricing necessary within that, but at this stage we haven’t had to exercise that lever to near the extent that we did in the past.

Next question, please.

Yes, our next question will be coming from Michael Cherny calling from Leerink Partners. Please go ahead, your line is open.

Good morning and thank you for taking the question. Maybe if I could dive a little bit more into the underlying pharma growth, if you can. You did a good job outlining some of the moving pieces on lost contract versus new. Is there any way you can give us a bit more color on where you expect the profit streams to lie from specialty, and then also a bit more color on the COVID hangover, just so that we can have a better understanding. I guess maybe the simple, straightforward question is where will you be on an exit run rate on pharma growth exiting the year, given all the moving pieces you have to start the year?

Yes, let me try to address a few of those pieces. Specialty is absolutely a key part of this story and why we still anticipate being able to grow this business next year. We highlighted in our comments that in fiscal ’24 for the year, we saw another year of 14% growth. You may recall at our investor day last year, the specialty business CAGR over the prior three years was anticipated at that time to be 14% as well, so another year of strong growth driven by the widespread investments that we have made and continue to make. We talked today about a couple of interesting growth drivers for the future, whether it’s our advanced therapy solutions business, the new venture with CVS for Averson focused on biosimilars. Biosimilars in general has been a rising tide type of benefit over the last several years, and of course then our acquisition of specialty networks, which closed in March and has an eight, nine-month type of year-over-year benefit tailwind, so these are all areas that are driving our specialty business to some degree in fiscal ’24, but they’re all examples of where we would expect that to continue to grow over fiscal ’25 to help mitigate for that contract non-renewal, that we think while that growth will be slower in ’25 due to that. I also made the comment in the remarks that even in spite of this overall revenue reduction for the enterprise for the pharma segment and the impact of that contract non-renewal, we still expect our specialty business to grow in fiscal ’25 in spite of that. That tells you that our run rate as we lap fiscal ’25 and that non-renewal, we would anticipate it to be very consistent with the long term algorithm that we’ve highlighted in the past, which from a profit perspective has been defined as low single-digit type of profit growth for our PD core business and double-digit growth for specialty, so we’ll continue to look at other opportunities to invest organically, as well as inorganically to continue to feed that growth.

Next question, please.

Our next question today will be coming from Erin Wright calling from Morgan Stanley.

Great, thanks. In terms of the fiscal ’25 guide, are there any changes in terms of how you were thinking just the Optum unwind in terms of stranded costs or otherwise, and just given the building contributions, whether it’s specialty networks or the new customer win with that Optum offset, I guess, how should we think about that cadence in terms of the split of first half versus second half, or however you want to define it, on an EPS perspective, given some of those moving pieces in the first half? Thanks.

Yes, I’ll have Aaron walk through some of the cadence [indiscernible], to your question, but I wanted to stress just upfront, what you should have heard from these messages are very, very similar words and phrases that we used last quarter. The plan is unchanged. Of course, we get a little bit smarter, we sharpen our pencils a little bit and we get a better understanding of where our exit rate is for ’24, but all the factors that we are talking about today with this business are very similar to what we walked through in the past, and of course all the investments that we made this last year. Aaron, a few thoughts on the cadence?

Sure, so the way to think about it is Optum was an existing customer with us until the end of our Q4, and you can see the results in Q4, we don’t need to go deeper on that. But what did also happen in Q4 was us being incredibly planful around the impacts to our operations, as well as to our financials of that customer unwind. We’ve talked in the past and we talked during our last earnings call around the three offsetting actions, the contribution of specialty networks, of course the new customer win, the expansion with existing customers as well as further cost optimization opportunities, and we’re pleased the team got on it, got ahead of it, and they’ve already been executing in that respect, and so the guidance we’re able to provide today, we view as relatively consistent with what we’ve provided in Q3, but with an additional degree of confidence because the plans are behind us and now we’re acting in that way. The non-renewal will impact our Q1- there’s no way to avoid that. They were a large, low margin customer, and as we’ve talked about, the new customers coming on board are largely back half-loaded, and so we will have a timing difference relative to prior years and that will impact certainly our revenue and profitability timing over the course of the year. There’s also a cash impact, right? The unwind of the negative working capital position there is a Q1 impact for us and a key reason why we are carefully monitoring our cash flow during the first quarter, of course balanced with the fact that we are delighted with the strong adjusted free cash flow and the strong cash balance at the end of our Q4. Look - on balance, the cost optimization is already in play, specialty networks is already in play, and we continue to work on the customer expansions and the new customer on-boarding, and we will make that successful as well.

Thank you. Our next question today will be coming from Allen Lutz calling from Bank of America. Please go ahead.

Good morning, and thanks for taking the questions. One for Aaron. Can you talk about how gross profit performed relative to your internal model, and then are you seeing any impact from insulin pricing changes or Humira share shifts to gross profit dollar growth? Then are there any insights or thoughts around a biosimilar launch for Stelara? Thanks.

I’ll start. Look, I would observe that our gross margin progression went largely as we anticipated over the course of the quarter and the year. We have a very complicated business managing between the various parts, and no real surprises from my chair in that way. The second part of the question was--?

Yes, let me take that. It was related to, I think, just the general impact of insulin pricing, but there’s also the Humira element there, so it’s probably a couple different questions. Within the quarter, we did, as Aaron had highlighted before, we saw of course the ongoing benefit of the GLP-1 growth, but we did have a similar offset as it relates to the pricing change for the WAC insulin adjustments that happened at the beginning of the calendar year. Until we get through the second quarter of fiscal ’25, we’d anticipate there to be a bit of an offset related to that price change. There was also a question around Humira and, I assume, just the biosimilar type of migration. We see that it’s started to move a little bit more. Certainly some of the actions that CVS has done more broadly in the marketplace seem to have moved things along a little bit further. It’s still fairly low penetration throughout the broad industry, but generally speaking, we have seen that start to pick up a little bit, I wouldn’t say meaningfully, within the quarter, maybe a little bit even afterwards, but it’s still at fairly low penetration rates. It’s one of the reasons why we’re so focused on biosimilars and with our joint venture with Averon, is just to continue to look for ways to increase access for patients that need that therapy at an affordable cost, so we’ll continue to do our part there. Next question please.

Our next question today will be coming from Kevin Caliendo of UBS. Please go ahead.

Thanks for taking my question. I’m just trying to triangulate some of the things we’ve learned this quarter about the GMPD business. You’re talking about winning more share of pocket. We’re seeing you make investments in domestic plants, we’ve seen shipping costs go higher. At the same time, we’ve seen Owens & Minor and Medline put up stronger than expected results, and McKesson and Henry Schein put up worse than expected results and guide lower in those segments. Is it maybe fair to say that you and your peers on the hospital side are moving downstream at all to try to capture greater percentage of the health system business that’s not just in the acute care side? Is that a trend that’s happening, and I guess the second part of that is the investments in domestic driven by the idea that now you could be more--because shipping costs are higher, costs overseas, tariffs are coming, that the domestic manufacturing can be more competitive in a price basis versus importing?

Yes, so it’s certainly true that GMPD is more acute focused customers, and we do benefit from the migration towards more of an ASC model. We do not participate widely in physician offices, so that’s an element. It’s nothing that we’ve called out as broad trends, so I don’t have much more to go on there, other than on a same store sales basis, we’re seeing the utilization fairly consistent this past year, generally speaking, that low single-digit type of range, so we are seeing that there’s like-for-like growth. What we’ve highlighted fairly consistently is that this last year was--or the end of ’23, beginning of ’24 was the inflection point for us. We were not growing with the market at that point. Over the course of ’24, we’ve largely grown with the market, plus or minus a point here or there, so very consistent with that low single-digit type of growth over--especially after our first quarter. We don’t think there’s widespread shifts there, but we definitely have an ASC presence that we do think we benefit from, but I wouldn’t call that a main driver of what we’re looking at. In terms of the investments we’re making, we did call out some domestic investments, but they’re not limited to domestic. We believe in a very diversified, competitive geographic footprint. We’ve stressed that specifically we don’t have manufacturing, direct manufacturing in China - that’s one of the related questions here as it relates to certainly the ongoing tariff risk, and I can also let you know that we only source less than 10% of our total Cardinal Health branded product in China, so specifically to China, we don’t have a large exposure. But we do have exposure beyond China, and Asia and near-shore Central, South America, we believe a diversified, broad supply base is important, as well as a domestic footprint. We have increased our investments across the supply chain to improve the resiliency, and there’s a couple of areas within the U.S. specifically - you’ve seen some of the tariffs related to syringes is a specific area of focus, and we happen to have that capability in the United States. That’s just one example of where we’re really doubling down on that investment. So yes, costs and freight are always a consideration - you know, we build a financial model behind all that and we look at the risks, but on this particular example, one example of where we’re really leaning in on that investment, that’s more about just ensuring our customers get the product they need. This is more of a volume opportunity than a pure cost and margin opportunity, so you’ve got to look at all those factors. Next question, please.

Yes sir. The next question today will be coming from Eric Coldwell of Baird. Please go ahead.

Thank you very much. I wanted to ask quickly about Medicaid disenrollment and the extent you’ve seen impacts in consumer or channel behavior as a result of that, and if so, could you specify where and possibly quantify those impacts? I think specifically, I’m probably tagging onto Kevin’s question and wondering if some of the shifts we’re seeing in the medical segment could be related to roughly 25 million people coming off of Medicaid here in the last several months. Thank you very much.

Yes, thanks for the question, Eric. Again, I think my answer is going to be fairly similar to what I said before, but in a different context. We have a very broad base of customers, very broad base of payors behind those customers, so we don’t have necessarily even the insight all the time as to where those reimbursements are coming from. The same store sales type of information, what we see more broadly is just not a lot of fluctuations and variations, and we’re not talking again of any type of growth rate above and beyond what we believe that underlying utilization is. Generally speaking, if there are some of those trends, at this stage I’m not seeing that as a meaningful driver to where our business is going.

Next question please.

Yes sir, our next question today will be coming from George Hill calling in from Deutsche Bank. Please go ahead.

Hey, good morning guys, thanks for taking the question. A two-parter. Number one, I guess Aaron, would you be willing to provide any more color on earnings cadence expectations for the year, particularly Q1 and Q2 versus the back half, given the large number of moving pieces? Then a quick one for Jason is we know you’ve got the new business coming on, we’ve got the United loss. Would just love an update on the competitive environment in drug distribution. This has been a pretty stable space for a while now. Just want to make sure that nothing’s changed, or nothing should be changing in the dynamic that we should be aware of. Thanks.

I’ll start. I would just observe that we’re being very thoughtful in the planning we’re doing for the year, given the number of moving pieces we have both within the pharma business and within the GMPD business, and of course keeping an eye on the three growth businesses within other. Within pharma, what we’ve reference is first half from a cadence perspective will be slightly down to flat versus prior year. That’s only natural given the customer unwind and the back ended nature of the new customer on-boarding. Largely, the drivers within the pharma business are consistent with what would have been true in previous years - Q3 will be where we see the branded inflation rolling through, and so not a lot of different news there that I would call out. From a med perspective, we’re very focused on executing against the plan. We’ve tried to be transparent every quarter about how we’re doing and where we see it going, which is why we were purposeful in calling out Q1 specifically as we push ahead. We’ve had great success during fiscal year ’25 and accomplished what we told you we were going to do, and we plan to do that again. Just want to be clear that we are investing in the business and there are some near term Q1 drivers that will make that rough number, what we call the up to $20 million as we carry forward. There’s no magic here, though - I want to be clear. The plan and the cadence is generally consistent with how we’ve described the GMPD improvement plan in the past. Of course, we have the benefit of the inflation mitigation now lapping as we push ahead, and of course we can’t forget the important topic of seasonality from a Q4 to Q1 perspective - we’ve called that out before, and that’s why you see a dip from the great results in Q4 into Q1.

As it relates to the second question, I’ll say what I said before - we’re 1% industry, so it’s competitive but stable. I would say that the vast majority of contracts don’t change hands period to period. These couple, several that have that more notable, there’s been several that have long term five-year types of agreements, so every five years there is the chance, opportunity or risk for that to occur, but again I’ll just stress the vast majority don’t. We feel really good about our positioning, competitive positioning. We know we’re competitive, we know that our message and our work and our results resonate with our customers. We’re very much focused on that experience, the service levels, the value initiatives and propositions behind it, the tools and platforms. We’ve talked about our InteLogix and our Atrix platforms for health systems as one example of not just going at them with price but going at them with value, and having true value components to those offerings, and we feel really good about where that positioning is, and that’s why we’ve been able to offset to the degree that we have.

Next question please.

Yes sir, the next question will be coming from Stephanie Davis of Barclays. Please go ahead.

Hi guys. This is Anna Grasinsky [ph] on for Stephanie. Congrats on the quarter, and thank you for taking our questions. I was hoping to hear more about your AI road map. You’ve highlighted AI and machine learning deployments within the InteLogix platform, and just wondering how we should think about additional AI use cases to improve efficiency and potential cost savings.

Yes, thanks for the question. It’s broad-based, it’s varied. We don’t call it out in every call in all areas, but it’s so broad, it really is everywhere. It’s in the core of how we operate. Examples of what we talked about today, without using the phrase AI, especially networks - you know, their PPS analytics is a great example of taking that data, electronic medical records and synthesizing that for manufacturers, as well as providers, and getting actionable insights. I mean, that is AI. When you look at some of the automation I’m commented on in our at-home solutions network, this is now over 25% of our sites just in the last 12 to 18 months. We’re launching a new footprint that is bringing in technology and automation in various forms into the manufacturing--or I’m sorry, into the distribution setting to be even more innovative, even more efficient and productive. As you mentioned, those other platforms, InteLogix, Atrix, working with Palantir and other partners to create value, and then I’m not even getting into the more basic use cases like customer service and back office. I guess I don’t want to just hit the same drumbeat everyone else is. What we’re trying to do in our communication is get beyond the buzzwords and really talk about the essence of where we’re driving our business, and we feel really good about that, and it’s definitely [indiscernible].

Next question, please.

Yes sir, we’ll now move to Elizabeth Anderson calling from Evercore. Please go ahead, your line is open.

Hey guys, thanks so much for the questions. I was wondering if you could maybe expand on your prior comments about two things. One, you talked about customer expansions a couple of times across the course of the call. Can you talk about what those are - generally speaking, are they people moving from pharma to increase in medical, are they moving across different pharma categories? How do we think about that? Then if we think about the cost cutting, obviously there’s some right-sizing for the contract change that you guys mentioned, but how do we think about some of the more--it sounds like some of those changes you’re putting through are sort of more structural, so how do we think about the long term benefits of those going forward? Thanks.

Yes, I’ll start. On the customer expansions, these are existing customer relationships where we are already a primary distributor for them, and they are expanding their footprint, whether it’s acquisitions or just taking on more of the business themselves, and we’re supporting their growth, so it’s an existing relationship and expanding upon that, so it’s committed in that sense, where we’re already there, and you can use BioPlus as one of the examples of what I’m talking about there. Perhaps Aaron, you can go into a little bit more detail on the [indiscernible]?

Sure, so as I commented earlier, the team did a great job of assessing our opportunities in the face of the customer non-renewal, but I guess I would go back and point out that at the end of the day, we operate a 1% operating margin business, so it’s important for us to always be mindful of the cost structure around us, but with a north star of how do we continue to ensure our customer service. We have been pleased that the reviews we undertook during Q4, the actions we identified will help us to offset the near term impact of customer loss, but more importantly they create a more efficient operational structure for us, and the changes are broad ranging across the enterprise with that north star ensuring we continue our customer service focus as we push ahead. Many of the changes have already been implemented and we’re operating in that new framework already. We continue to assess what are the productive opportunities, and I also would emphasize that the ideas for these changes are coming from our broader teams as they look around and say, okay, how can we operate better in support of our existing customers and the new customers on the line.

Next question please.

Yes sir, we’ll now move to Stephen Baxter of Wells Fargo. Please go ahead.

Yes, hi. Thanks. I just wanted to ask a couple about the restatement to GMPD. It sounds like you’re saying the higher GMPD base post-restatement in 2024 doesn’t’ change the run rate, because you’re removing out-of-period items. Is that the right way to think about it, so there’s no comparability issue with the $175 million target on that higher base? I guess that’s the first question. Then based on the restatement that you provided, I think the cumulative profit in the business from 2022 to 2024 is $25 million or $30 million higher than previous. I’m just trying to understand why those things don’t net out if we’re thinking about timing issues here. Thank you.

Yes, appreciate the question. The answer is there is no comparability issue. The 175 is unimpacted by the revisions that we provided in the financials today. The revisions we provided were for the three-year period. There will be--there is an impact of shifting of income or expense into the prior periods as well, which is why you’re not seeing direct comparability as we carry forward. I do want to emphasize, though, that part of our operation here is building and maintaining a strong [indiscernible] environment, and as we identified the issue in the Edgepark part of our at-home business, which is part of other, it was a revenue recognition issue tied to a business which does less than half a percent of our overall revenue base. We were careful to do the right thing and disclose, and at the same time in partnership with our auditors decided that we would reflect the feedback we’ve gotten from this community and others around comments around non-recurring adjustments in prior periods, etc., and so now we walk into fiscal ’25 not only with comparability but with a clean set of financials, unimpacted by timing to be able to talk about our progress as we carry forward.

Next question please.

Yes sir, the next question will be coming from Charles Rhyee with TD Cowen. Please go ahead.

Hi, this is Lucas on for Charles. Thanks for taking the questions. I wanted to ask about the other segment. Can you talk about what’s expected from OptiFreight, nuclear and at-home in fiscal ’25 in terms of growth? Should we be thinking about any of these businesses outperforming the 10% segment target that you’ve set?

Well from a guidance perspective, we provide guidance for other on an aggregated basis, but I do want you to take away the enthusiasm present in Jason’s comments and his tone of voice around the opportunity we think that each of these three businesses presents to Cardinal Health as we carry forward. The businesses are unique. They are managed differently. We aggregate them from a financial perspective. It’s also the case that we are investing in each of those businesses, we have in ’24 and we are in ’25. At-home has recently opened two new distribution points and is investing in automation. OptiFreight has continued to invest in its digital platform and service of its customer experience. The nuclear business, we’ve talked at length about expanding the PET network as well as our excitement about the theranostic opportunities that that business presents. Again, as I go back to the financial guide, part of what you’re seeing in the other basis is we are presenting a consistent picture on an aggregated view, which reflects in some cases we’ll be investing in a year or a month while reaping the benefit in the same year or month from other parts of the portfolio. Jason?

Yes, I would say the one thing we did clarify in the prior comments is that all three businesses are expected to contribute to that growth in fiscal ’25, and we are investing--you know, fiscal ’24 was an especially heavy investment period, but we are continuing to invest across the range. Just one example to put into perspective is we talked a lot about our investments in our nuclear and precision health solutions business. This is a business that we’ve highlighted, theranostics now just with our second phase of expansion that we announced about a year ago, or this last year, and then we also have talked about some PET expansion. From a fiscal ’24 to ’26, that’s about $100 million, mainly capital that we’re investing into that business, but it’s representative of the big investments that we’re making in addition to the three different distribution centers in at-home solutions that Aaron had mentioned are very representative of the inputs that we’re putting into these businesses, because we deeply believe in their ability to continue to grow, benefit from the secular trends they each enjoy, but then also reflecting the leadership position we have in each, and that is then further bolstered by these very specific investments.

Next question please.

Thank you sir. Ladies and gentlemen, our last question today will be coming from Daniel Grosslight of Citi. Please go ahead.

Hi, thanks for taking the question, and congrats on a strong quarter. Was hoping to get a bit more detail on Averon. Will that just be serving CVS at this point, and how does that kind of interact with Cordavis, and then are there any purchase obligations or quarterly payments associated with that? Then lastly, when does that agreement renew?

Okay, so you crammed in about four there. Averon, the first specific question on Averon was--?

Just broadly speaking, more color.

Yes, so I referenced it a few different times, so I think maybe there’s a more specific question behind it. Oh - I think the question was, does it just service CVS? The answer is no. It’s a consistent concept as what we did with Red Oak Sourcing, reflecting that we both have different needs, different customers if you will, and can jointly benefit those patients through combining our capabilities in this space, so we would expect to operate it in a similar way, where we have different benefits associated with that. There are--I think what you’re talking about, there’s not the same type of payment structure and schedule that we have for Red Oak Sourcing, kind of equalization payments if you will, so that structure does not exist with this. It is structured quite a bit differently in that regard. Then in terms of--I think there was a renewal question there about CVS, and so the contract goes through--the distribution contract goes through ’27, and then the Red Oak agreement goes through ’29, so this is certainly outside of those agreements and it’s very much an example of the type of partnership that we look to have with any and all of our customers in various ways to ensure that we’re thinking about how better to serve those underlying patients.

Thank you, Mr. Hollar. We don’t have any further questions, so I’d like to turn the call back over to you for any additional or closing remarks. Thank you.

Yes, thank you, and thank you all for joining us. In addition the usual pleasantries I have at this point in the call, I do want to step back for just a minute, reflecting that given it’s our year-end as well as additional guidance, I know that there was a lot to digest within this, but I hope that we clarified many of your points today. I do want to end where I started and just re-emphasize those same three key points I had at the very beginning of the commentary today. First of all, we finished the year with terrific momentum. We grew our earnings per share by 29% for both the quarter and the fiscal year. You add that on top of the growth that we saw last year, that’s a nearly 50% increase in our EPS over the last couple of years, driven by performance across the board but really strong performance in our largest, most significant business, our pharma segment, growing despite having some of those impacts in the quarter from that contract unwind. But we’re also seeing very good utilization across the enterprise, whether it’s pharma as well as GMPD. We see that this industry continues to have a lot of need within the marketplace. That in part is driving our GMPD, but really that $240 million improvement that we saw for that business this year is being driven by the successful mitigation of inflation, a long hard journey but we’ve gotten there, and now we’re able to focus on driving the business going forward. Our other businesses, we’re seeing robust demand across the board, utilization but secular trends as well. Really excited about the ongoing growth there - double digit 10% growth in 2025 while continuing to invest in the business. Cash flow -…

Thank you very much, sir. Ladies and gentlemen, that will conclude today’s conference. We thank you for your attendance and you may now disconnect. Have a good day, and goodbye.